These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15293370)

  • 41. Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
    Su VY; Chang YS; Hu YW; Hung MH; Ou SM; Lee FY; Chou KT; Yang KY; Perng DW; Chen TJ; Liu CJ
    Medicine (Baltimore); 2016 Feb; 95(5):e2427. PubMed ID: 26844454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-blocker therapy in heart failure: pathophysiology and clinical results.
    Carson PE
    Curr Probl Cardiol; 1999 Jul; 24(7):421-60. PubMed ID: 10403092
    [No Abstract]   [Full Text] [Related]  

  • 43. Selective beta-blockers and mortality from heart failure.
    Seth S; Naik N; Mohan A
    Natl Med J India; 1999; 12(5):225-6. PubMed ID: 10613003
    [No Abstract]   [Full Text] [Related]  

  • 44. [Adrenergic beta inhibitors in heart insufficiency: which and when?].
    Coutinho J
    Rev Port Cardiol; 2001 Mar; 20 Suppl 3():17-25. PubMed ID: 11409070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Beta-adrenolytics in heart failure--are they all really equal?].
    Filipiak KJ; Opolski G
    Przegl Lek; 2005; 62 Suppl 2():39-42. PubMed ID: 16623117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Choosing metoprolol or carvedilol in heart failure (a pre-COMET commentary).
    Rajput FS; Gnanasekeram H; Satwani S; Davenport JD; Gracely EJ; Gopalan R; Narula J
    Am J Cardiol; 2003 Jul; 92(2):218-21. PubMed ID: 12860230
    [No Abstract]   [Full Text] [Related]  

  • 47. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
    Ahmed A
    Eur J Heart Fail; 2003 Dec; 5(6):709-15. PubMed ID: 14675848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The role of beta-adrenergic blocking agents in treatment of heart failure].
    Witkowska M
    Pol Arch Med Wewn; 1999 Jan; 101(1):9-14. PubMed ID: 10592722
    [No Abstract]   [Full Text] [Related]  

  • 49. [Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Kawano S
    Nihon Rinsho; 2007 May; 65 Suppl 5():91-7. PubMed ID: 17571371
    [No Abstract]   [Full Text] [Related]  

  • 50. Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.
    Metra M; Nodari S; Boldi E; Dei Cas L
    Curr Cardiol Rep; 2000 May; 2(3):252-7. PubMed ID: 10980900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [COMET: metoprolol].
    Handa S
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():521-5. PubMed ID: 17511103
    [No Abstract]   [Full Text] [Related]  

  • 52. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
    Lee S; Spencer A
    J Fam Pract; 2001 Jun; 50(6):499-504. PubMed ID: 11401736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of beta blockers on morbidity and mortality in heart failure.
    Jafri SM
    Heart Fail Rev; 2004 Apr; 9(2):115-21. PubMed ID: 15516859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carvedilol versus other beta-blockers in heart failure.
    Doggrell SA
    Expert Opin Investig Drugs; 2001 May; 10(5):971-80. PubMed ID: 11322870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
    Bristow MR; Feldman AM; Adams KF; Goldstein S
    J Card Fail; 2003 Dec; 9(6):444-53. PubMed ID: 14966783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.
    Shepherd AM
    J Card Fail; 2003 Dec; 9(6):454-7. PubMed ID: 14966784
    [No Abstract]   [Full Text] [Related]  

  • 58. Beta-blockers for heart failure: why you should use them more.
    Ong HT; Kow FP
    J Fam Pract; 2011 Aug; 60(8):472-7. PubMed ID: 21814642
    [No Abstract]   [Full Text] [Related]  

  • 59. Use of beta-blockers for heart failure in patients with diabetes mellitus.
    Giles TD
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):32-7. PubMed ID: 19667606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.